Zai Lab Limited

ZLAB

US98887Q1040

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zai Lab Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.55 USD

Average target price

51.37 USD

Spread / Average Target

+138.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ZAI LAB LIMITED	-21.15%	2.14B
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-12.32%	33.03B
UCB	+54.88%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-17.39%	15.12B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.42%	8.9B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
21.55 ^USD	+0.14%		+29.20%	-21.15%

May. 14	Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	MT
May. 14	Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	CI

Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	May. 14	MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China	May. 14	CI
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher	May. 13	MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro	May. 13	MT
Zai Lab's Cancer Drug Gets NDA Approval in China	May. 12	MT
Zai Lab's Shares Rise After Q1 Beat	May. 09	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower Thursday	May. 09	MT
Top Premarket Gainers	May. 09	MT
Transcript : Zai Lab Limited, Q1 2024 Earnings Call, May 09, 2024	May. 09
Zai Lab Q1 Loss Widens Despite Higher Revenue	May. 08	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading	May. 06	MT
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher	May. 03	MT
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	Apr. 17	MT
Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024	Apr. 11	MT
Zai Lab Changes Record Date	Apr. 10	MT
Zai Lab Grants Share Options, Restricted Share Units to Eligible Personnel	Apr. 04	MT
Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint	Apr. 01	MT
Zai Lab Reports Lesser Loss in 2023	Mar. 27	MT
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients	Mar. 27	MT
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	Mar. 27	CI
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	Mar. 20	MT
Asian Equities Traded in the US as American Depositary Receipts End Week Lower in Friday Trading	Mar. 15	MT
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate for Treatment of Solid Tumors	Mar. 13	CI
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	Mar. 13	MT
Transcript : Zai Lab Limited, 2023 Earnings Call, Feb 28, 2024	Feb. 28